NO975688L - Differensialanalyse for ulcerös kolitt, primær skleroserende cholangitt og type 1 autoimmunhepatitt - Google Patents

Differensialanalyse for ulcerös kolitt, primær skleroserende cholangitt og type 1 autoimmunhepatitt

Info

Publication number
NO975688L
NO975688L NO975688A NO975688A NO975688L NO 975688 L NO975688 L NO 975688L NO 975688 A NO975688 A NO 975688A NO 975688 A NO975688 A NO 975688A NO 975688 L NO975688 L NO 975688L
Authority
NO
Norway
Prior art keywords
ulcerative colitis
sclerosing cholangitis
primary sclerosing
type
autoimmune hepatitis
Prior art date
Application number
NO975688A
Other languages
English (en)
Other versions
NO321090B1 (no
NO975688D0 (no
Inventor
Stephan Targan
Alda Vidrich
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of NO975688D0 publication Critical patent/NO975688D0/no
Publication of NO975688L publication Critical patent/NO975688L/no
Publication of NO321090B1 publication Critical patent/NO321090B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19975688A 1995-06-07 1997-12-05 Fremgangsmate for pavisning av naervaer av perinukleaert, antinoytrofilt, cytoplasmatisk antistoff (p-ANC) forbundet med type 1 autoimmunhepatitt og primaer, skleroserende cholangitt i en prove og fremgangsmate for a skille primaer, skleroserende cholangitt fra type 1 autoimmunhepatitt. NO321090B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/480,753 US5830675A (en) 1993-03-10 1995-06-07 Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
PCT/US1996/008758 WO1996041183A1 (en) 1995-06-07 1996-06-05 Differential assay for ulcerative colitis, primary sclerosing cholangitis and type 1 autoimmune hepatitis

Publications (3)

Publication Number Publication Date
NO975688D0 NO975688D0 (no) 1997-12-05
NO975688L true NO975688L (no) 1998-02-05
NO321090B1 NO321090B1 (no) 2006-03-13

Family

ID=23909233

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975688A NO321090B1 (no) 1995-06-07 1997-12-05 Fremgangsmate for pavisning av naervaer av perinukleaert, antinoytrofilt, cytoplasmatisk antistoff (p-ANC) forbundet med type 1 autoimmunhepatitt og primaer, skleroserende cholangitt i en prove og fremgangsmate for a skille primaer, skleroserende cholangitt fra type 1 autoimmunhepatitt.

Country Status (12)

Country Link
US (1) US5830675A (no)
EP (1) EP0846266B1 (no)
JP (1) JP3386815B2 (no)
AT (1) ATE231972T1 (no)
AU (1) AU705480B2 (no)
CA (1) CA2223642C (no)
DE (1) DE69626026T2 (no)
IL (1) IL122480A0 (no)
MX (1) MX9709440A (no)
NO (1) NO321090B1 (no)
NZ (1) NZ310079A (no)
WO (1) WO1996041183A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2992497A (en) * 1996-04-12 1997-11-07 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone h1
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US6033864A (en) * 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6183951B1 (en) * 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6599509B2 (en) * 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
DE19805815C1 (de) * 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostikum zum Erkennen der autoimmunen Hepatitis
US20080193945A1 (en) * 2002-06-25 2008-08-14 Index Diagnostics Ab Method and Kit for the Diagnosis of Ulcerative Colitis
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US20040076960A1 (en) * 2002-10-18 2004-04-22 Taylor Kent D. Methods of using a NOD2/CARD15 haplotype to diagnose Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
CN1316250C (zh) * 2005-05-01 2007-05-16 李小峰 中性粒细胞抗原底片的制备方法
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
GB0621454D0 (en) 2006-10-27 2006-12-06 Ucl Business Plc Goal directed therapy for liver failure
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2009082298A1 (en) * 2007-12-20 2009-07-02 Index Diagnostics Ab Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd
AU2009314259B2 (en) 2008-11-11 2015-06-11 Nestec S.A. Methods for prediction of inflammatory bowel disease (IBD) using serologic markers
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
EP2419529B1 (en) 2009-04-14 2015-05-20 Nestec S.A. Inflammatory bowel disease prognostics
EP2445517B1 (en) 2009-06-25 2014-07-30 Nestec S.A. Methods for diagnosing irritable bowel syndrome
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
EP2707504A1 (en) 2011-05-10 2014-03-19 Nestec S.A. Methods of disease activity profiling for personalized therapy management
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
JP2015502740A (ja) 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
CN102707055A (zh) * 2012-06-11 2012-10-03 郑州安图绿科生物工程有限公司 一种联合或单独检测自身免疫性肝病相关抗体的试剂盒及其检测方法
CN102955027A (zh) * 2012-06-11 2013-03-06 郑州安图绿科生物工程有限公司 检测自身免疫性肝病相关抗体抗lc-1抗体的试剂盒及其检测方法
AU2013326070A1 (en) 2012-10-05 2015-04-23 Société des Produits Nestlé S.A. Methods for predicting and monitoring mucosal healing
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CA2932571A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
EP3077538A1 (en) 2013-12-03 2016-10-12 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
EP3227685A1 (en) 2014-12-02 2017-10-11 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
KR102464372B1 (ko) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3273238A1 (en) * 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
SG11202003216QA (en) 2017-10-10 2020-05-28 Prometheus Biosciences Inc Methods for monitoring vedolizumab treatment
CN110604743B (zh) * 2019-07-23 2021-08-17 四川大学 中性粒细胞在制备治疗和/或预防自身免疫性肝炎的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292667A (en) * 1988-06-29 1994-03-08 The General Hospital Corporation Detection and treatment of ulcerative colitis
US5091303A (en) * 1989-10-27 1992-02-25 The General Hospital Corporation Diagnosis of wegener's granulomatosis
WO1992002819A2 (en) * 1990-08-10 1992-02-20 The Regents Of The University Of California Assay for ulcerative colitis and primary sclerosing cholangitis
US5238813A (en) * 1990-12-18 1993-08-24 Washington University Diagnostic method for nephritis
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
ATE193601T1 (de) * 1993-03-10 2000-06-15 Cedars Sinai Medical Center Verfahren zum selektiven nachweis von perinuklearen anti-neutrophilen cytoplasmischen antikörpern bei ulzerativen kolitis oder primärer sclerotischer cholangitis

Also Published As

Publication number Publication date
JPH11507130A (ja) 1999-06-22
CA2223642A1 (en) 1996-12-19
CA2223642C (en) 2005-08-16
EP0846266B1 (en) 2003-01-29
NO321090B1 (no) 2006-03-13
ATE231972T1 (de) 2003-02-15
JP3386815B2 (ja) 2003-03-17
EP0846266A4 (en) 2001-08-29
MX9709440A (es) 1998-06-30
IL122480A0 (en) 1998-06-15
EP0846266A1 (en) 1998-06-10
US5830675A (en) 1998-11-03
NO975688D0 (no) 1997-12-05
DE69626026T2 (de) 2004-01-22
DE69626026D1 (de) 2003-03-06
NZ310079A (en) 2000-02-28
AU6040496A (en) 1996-12-30
AU705480B2 (en) 1999-05-20
WO1996041183A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
NO975688L (no) Differensialanalyse for ulcerös kolitt, primær skleroserende cholangitt og type 1 autoimmunhepatitt
EP0615129A3 (en) Method for selectively detecting cytoplasmic, anti-neutrophilic antibodies to ulcerative colitis or primary sclerosing cholangitis.
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
NO964015L (no) Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer
EP0254081A3 (en) Method of detecting specific protein
BR9100924A (pt) Linha de celulas de hibridoma,mutantes,anticorpos,processo para a preparacao de uma linha de celulas de hibridoma,processo para a preparacao de anticorpos,processo e agente para a prova imunologica de metolacloro,derivado de metolacloro e processo para sua preparacao
ES8705232A1 (es) Un metodo para preparar un anticuerpo monoclonal destinado autilizarse como auxiliar de diagnostico para detectar cancerde pulmon
FI104219B1 (fi) Diagnostinen menetelmä ja testaustarvikesarja multippeliskleroosin määrittämiseksi
HUT60785A (en) Immunological measuring methods
ATE208041T1 (de) A-protein als diagnostikum für krebs
IL113346A (en) Method to identify immunocompromised patients at high risk for cryptococcosis
NO931613L (no) Fremgangsmaate for bestemming av sensiteten og/eller det spesifikke ved et proberingssystem for sporing av antistoffer
TW246718B (en) Immunoassay for detecting HCV IgM antibody

Legal Events

Date Code Title Description
MK1K Patent expired